Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. (Currently amended) Pharmaceutical cream preparation in the form of an oil-in-water (o/w) emulsion for topical application in the treatment and/or prevention of skin diseases, characterized in that said preparation comprises the following constituents in the lipophilic phase:

(i) as the active ingredient, an optionally substituted 1-phenyl-2-(1H)-pyridone compound or a pharmaceutically acceptable salt thereof;

(ii) at least one surface-active solubilizer with an HLB value in the range 15-20, said surface-active solubilizer being selected from the group consisting of diethylene glycol monoethyl ether, polyethylene/propylene glycol copolymers, cyclodextrins, glyceryl monostearates, sorbitan esters, polyoxyethylenesorbitan acid esters, polyvinyl alcohol, sodium laurylsulfate (anionic) and glyceryl monooleates;

(iii) at least one emulsifier with an HLB value in the range 8-15, said emulsifier being selected from the group consisting of anionic and non-ionic emulsifiers, anionic emulsifying waxes, cetyl alcohol, cetylstearyl alcohol, stearic acid, oleic acid, polyoxyethylene/polyoxy-propylene block polymers, addition products of 2 to 60 mol of ethylene oxide and castor oil and/or hydrogenated castor oil, wool wax oil (lanolin), sorbitan esters, polyoxyethylenalkyl esters, polyoxyethylenesorbitan fatty acid esters and polyvinyl alcohol; and

(iv) optionally other excipients and additives selected from the group comprising triglycerides, penetration enhancers, preservatives and antioxidants, said preparation being substantially free of phospholipids.

2. (Currently amended) Preparation according to Claim 1, characterized in that it comprises the oily phase in a proportion ranging from 20 to 80% by weight and the aqueous

phase in a proportion ranging from 80 to 20% by weight, based on the total weight of the preparation ~~according to the invention~~.

3. (Previously presented) Preparation according to Claim l, characterized in that it comprises the oily phase in a proportion ranging from 24.1 to 84.1% by weight and the aqueous phase in a proportion ranging from 75.9 to 15.9% by weight, based on the total weight of the preparation.

4. (Previously presented) Preparation according to Claim 1, characterized in that it comprises the active ingredient in an amount of 0.5-9% by weight based on the total weight of the preparation.

5. (Previously presented) Preparation according to Claim 1, characterized in that it comprises the surface-active solubilizer in a concentration of 5-65% by weight based on the total weight of the preparation.

6. (Previously presented) Preparation according to Claim 1, characterized in that it comprises the emulsifier in a concentration of 3-30% by weight based on the total weight of the preparation.

7. (Previously presented) Preparation according to Claim 1, characterized in that it comprises as the active ingredient a substituted pyridone of general formula (I):



or a pharmaceutically acceptable salt thereof, in which R_1 is one of (C_1-C_4)alkyl, carboxyl 0753

(-COOH) or -COOalkyl(C_1-C_4) and R_2 is one of (C_1-C_4)alkyl, carboxyl (-COOH), -COOalkyl(C_1-C_4) and hydrogen.

8. (Previously presented) Preparation according to Claim 7, characterized in that when present (C_1-C_4)alkyl and alkyl(C_1-C_4) of R_1 and R_2 are independently selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, and t-butyl.

9. (Previously presented) Preparation according to Claim 7, characterized in that it contains as the active ingredient a compound of formula (I) in which R_1 is (C_1-C_4)alkyl and R_2 is hydrogen or (C_1-C_4)alkyl.

10. (Withdrawn) Preparation according to Claim 1, characterized in that the active ingredient is a pharmaceutically acceptable salt as an alkali metal or alkaline earth metal salt of the carboxyl-substituted compound of formula (I), or a salt of the compound of formula I which does not contain a carboxyl group with oxalic acid or succinic acid.

11. (Previously presented) Preparation according to Claim 1, characterized in that it comprises one of the following compounds as the active ingredient:

5-methyl-1-p-tolyl-2-(1H)-pyridone
3-methyl-1-phenyl-2-(1H)-pyridone
3-ethyl-1-phenyl-2-(1H)-pyridone
4-isopropyl-1-phenyl-2-(1H)-pyridone
5-methyl-1-phenyl-2-(1H)-pyridone
3-methyl-1-carboxyphenyl-2-(1H)-pyridone
5-carboxy-1-phenyl-2-(1H)-pyridone
4-carboxymethyl-1-phenyl-2-(1H)-pyridone
5-t-butyl-1-(p-carboxyethylphenyl)-2-(1H)-pyridone.

12-13. (Canceled)

14. (Previously presented) Preparation according to Claim 1, characterized in that the triglyceride is selected from the group consisting of medium-chain and high-molecular triglycerides.

15. (Previously presented) Preparation according to Claim l, characterized in that the penetration enhancer is selected from the group consisting of isopropyl myristate, oleic acid, sodium laurylsulfate and 1,2-propanediol.

16. (Previously presented) Preparation according to Claim 1, characterized in that it also comprises at least one superfatting agents, solvents, consistency regulators and/or hydrotropic agents.

17. (Previously presented) Preparation according to Claim 1, characterized in that it comprises the following components:

(a) 3-7% by weight of active ingredient
(b) 3-30% by weight of emulsifier
(c) 5-65% by weight of surface-active solubilizer
(d) 5-30% by weight of triglyceride
(e) 2-20% by weight of penetration enhancer
(t) 2-20% by weight of superfatting agent
(g) 3-30% by weight of consistency regulator
(h) 0.01-3% by weight of preservative
(i) 0.1-5% by weight of antioxidant
(k) 1-50% by weight of solvent
(1) purified water balance to 100% by weight.

18. (Previously presented) Preparation according to Claim 1, characterized in that it comprises the following components:

- 3-7% by weight of active ingredient
- 5-12.5% by weight of cetylstearyl alcohol
- 10-45% by weight of macrogol 15-hydroxystearate
- 7-20% by weight of medium-chain triglyceride
- 3-10% by weight of propanediol
- 3-10% by weight of decyl oleate
- 5-12.5% by weight of stearic acid
- 0.02-3% by weight of sodium methylparaben and sodium propylparaben
- 0.2-3% by weight of sodium metabisulfite
- 1-50% by weight of solvent
- purified water balance to 100% by weight.

19. (Withdrawn) Process for the production of a preparation according to Claim 1, characterized in that the lipophilic constituents are melted together and the melt is heated to 60-80°C in one apparatus, and the aqueous phase is heated to the same temperature in a separate apparatus, the aqueous phase is then incorporated into the oily phase and the mixture is emulsified until homogeneous and stirred until it forms a semisolid cream, the pH optionally being adjusted to 5-7.5.

20. (Canceled)

21. (Withdrawn) A method comprising treatment or prophylaxis of a skin disease selected from diseases of a fibrotic nature, fibrous lesions, multiple warts, contact dermatitis, and keloids or promoting the healing of burns or post-operative wound care comprising applying the preparation of Claim 1 to skin.